NCT01845077 - Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions

Healthy

Interventions

DRUG

2x500 mg Metformin (Glumetza)

2 tablets

DRUG

5 mg Linagliptin/1000 mg Metformin FDC

FDC tablet

DRUG

5 mg Linagliptin (Tradjenta)

1 tablet

DRUG

5 mg Linagliptin (Tradjenta)

1 tablet

DRUG

3x500 mg Metformin (Glumetza)

3 tablets

DRUG

5 mg Linagliptin (Tradjenta)

1 tablet

DRUG

2 x 500 mg Metformin (Glumetza)

2 tablets

DRUG

5 mg Linagliptin/1000mg Metformin FDC

FDC Tablet

DRUG

2 x 2.5 mg Linagliptin/750 mg Metformin FDC

2 FDC tablets

Trial Locations (1)

1288.8.1 Boehringer Ingelheim Investigational Site, Austin